SEHK:9995Biotechs
Assessing RemeGen (SEHK:9995) Valuation After Its Turnaround To Full-Year Profit
Why RemeGen’s latest earnings matter for shareholders
RemeGen (SEHK:9995) has drawn fresh attention after reporting full year 2025 results, with sales of CN¥3,251.05 million and net income of CN¥708.52 million, compared with a net loss a year earlier.
See our latest analysis for RemeGen.
The earnings swing back to profit appears to have coincided with strong momentum, with a 1 month share price return of 8.76% and a year to date share price return of 20.57%. The 1 year total shareholder...